We are live on ! Find out more
IHAM

Integral Health Asset Management Portfolio holdings

AUM $2.09B
1-Year Est. Return 112.84%
This Fund
S&P 500
This Quarter Est. Return
-6.53%
1 Year Est. Return
+112.84%
3 Year Est. Return
+485.32%
5 Year Est. Return
+783.01%
10 Year Est. Return
–
AUM
$384M
AUM Growth
+$22.9M
Cap. Flow
+$49.3M
Cap. Flow %
12.82%
Top 10 Hldgs %
35.81%
Holding
89
New
18
Increased
39
Reduced
11
Closed
18

Top Buys

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$9.14M
2
CRSP icon
CRISPR Therapeutics
CRSP
+$7.54M
3
GH icon
Guardant Health
GH
+$6.84M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$6.76M
5
MRK icon
Merck
MRK
+$5.91M

Top Sells

Rank Stock Value
1
MCK icon
McKesson
MCK
+$13.7M
2
ABT icon
Abbott
ABT
+$9.85M
3
FATE icon
Fate Therapeutics
FATE
+$7.61M
4
ABBV icon
AbbVie
ABBV
+$6.77M
5
LH icon
Labcorp
LH
+$6.28M

Sector Composition

Rank Sector Weight
1 Healthcare 97.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CI icon
26
Cigna
CI
$72.4B
$5.99M 1.56%
+25,000
New +$5.85M
HRTX icon
27
Heron Therapeutics
HRTX
$61.3M
$5.72M 1.49%
1,000,000
+250,000
+33% +$1.83M
ONEM
28
DELISTED
1Life Healthcare
ONEM
$5.54M 1.44%
500,000
+225,000
+82% +$2.52M
JAZZ icon
29
Jazz Pharmaceuticals
JAZZ
$16.1B
$5.45M 1.42%
+35,000
New +$5.08M
KURA icon
30
Kura Oncology
KURA
$882M
$5.42M 1.41%
337,000
+252,000
+296% +$3.64M
SIBN icon
31
SI-BONE Inc
SIBN
$843M
$5.31M 1.38%
235,000
+60,000
+34% +$1.24M
ISRG icon
32
Intuitive Surgical
ISRG
$142B
$4.83M 1.26%
+16,000
New +$4.67M
AGL icon
33
Agilon Health
AGL
$1.45B
$4.44M 1.15%
7,000
+2,000
+40% +$1.03M
KROS icon
34
Keros Therapeutics
KROS
$211M
$4.41M 1.15%
81,000
+46,000
+131% +$2.36M
ACRS icon
35
Aclaris Therapeutics
ACRS
$871M
$4.1M 1.07%
238,000
+38,000
+19% +$518K
ZBH icon
36
Zimmer Biomet
ZBH
$18.5B
$3.84M 1%
+30,000
New +$3.62M
NTLA icon
37
Intellia Therapeutics
NTLA
$1.68B
$3.63M 0.95%
50,000
– –
NVRO
38
DELISTED
NEVRO CORP.
NVRO
$3.62M 0.94%
50,000
+15,000
+43% +$1.08M
INSM icon
39
Insmed
INSM
$29B
$3.52M 0.92%
150,000
+70,000
+88% +$1.63M
ARCT icon
40
Arcturus Therapeutics
ARCT
$214M
$3.37M 0.88%
125,000
+60,000
+92% +$1.53M
ZLAB icon
41
Zai Lab
ZLAB
$2.92B
$3.3M 0.86%
+75,000
New +$3.63M
NBIX icon
42
Neurocrine Biosciences
NBIX
$16.5B
$3.28M 0.85%
+35,000
New +$2.97M
BIIB icon
43
Biogen
BIIB
$30.1B
$3.16M 0.82%
15,000
-20,000
-57% -$4.35M
MIRM icon
44
Mirum Pharmaceuticals
MIRM
$5.99B
$3.08M 0.8%
140,000
+40,000
+40% +$816K
QURE icon
45
uniQure
QURE
$3.12B
$3.07M 0.8%
170,000
+70,000
+70% +$1.22M
RGNX icon
46
Regenxbio
RGNX
$703M
$2.99M 0.78%
90,000
+15,000
+20% +$417K
TFX icon
47
Teleflex
TFX
$5.91B
$2.84M 0.74%
+8,000
New +$2.63M
AKRO
48
DELISTED
Akero Therapeutics
AKRO
$2.84M 0.74%
200,000
+115,000
+135% +$2.01M
REPL icon
49
Replimune Group
REPL
$1.15B
$2.8M 0.73%
165,000
+65,000
+65% +$1.23M
ATRA icon
50
Atara Biotherapeutics
ATRA
$80.6M
$2.79M 0.73%
12,000
+4,000
+50% +$1.27M
1
2
3 4

Similar funds

CL
CSS LLC Chicago, Illinois $2.09B AUM 58.96% 1-Year Est. Return
ACM
Analog Century Management New York $2.09B AUM 186.85% 1-Year Est. Return
ACG
Aventail Capital Group New York $2.09B AUM 43.81% 1-Year Est. Return
NSUP
NLB Skladi upravljanje premozenja Ljubljana $2.09B AUM
TP
Third Point New York $2.08B AUM 27.04% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.08B AUM
TA
TruWealth Advisors Metairie, Louisiana $2.08B AUM 21.15% 1-Year Est. Return
AG
Avala Global New York $2.08B AUM 87.66% 1-Year Est. Return

Integral Health Asset Management's Q1 2022 Portfolio in Review

As of Q1 2022, Integral Health Asset Management held 89 positions worth $384M, up 6.3% from $361M the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Integral Health Asset Management deployed $49.3M of net new capital in Q1 2022, opening 18 new positions and adding to 39 existing holdings. Its largest new stake was CRISPR Therapeutics: 120,000 shares worth $7.53M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 97% a quarter earlier.

On the sell side, the largest reduction was Centene, an estimated $6.15M trimmed.

  • Integral Health Asset Management's largest Q1 2022 buy was CRISPR Therapeutics: 120,000 shares worth $7.53M.
  • Integral Health Asset Management added most to Elevance Health in Q1 2022, an estimated $9.14M increase.
  • Integral Health Asset Management's biggest Q1 2022 reduction was Centene, cutting an estimated $6.15M.
  • Integral Health Asset Management fully exited McKesson in Q1 2022, selling an estimated $13.7M.
  • Integral Health Asset Management's ten largest holdings make up 36% of its $384M portfolio in Q1 2022.
  • Integral Health Asset Management opened 18 new positions and closed 18 in Q1 2022.
  • Integral Health Asset Management's portfolio value rose 6.3% quarter-over-quarter to $384M.

Based on Integral Health Asset Management's 13F filing for Q1 2022, filed 12 May 2022.